Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28657587 | 0.80 | FYN (0.32) | FYNPDGFRBCASP3SENP8SENP7 | |
| SCHEMBL28321743 | 0.79 | CYP2A6 (0.38) | CYP2A6CYP2B6CYP2E1PDGFRB | |
| SCHEMBL13078874 | 0.75 | METAP2 (0.32) | NPC1 | |
| Thiophene SCHEMBL28181534 | 0.73 | AKT1 (0.38) | CYP2A6FYNCYP2B6CYP2E1NPC1 | |
| SCHEMBL5612895 | 0.72 | LMNA (0.43) | NPC1CYP3A4CYP2C9CYP2C19GSK3B | |
| SCHEMBL2024760 | 0.71 | — | — | |
| SCHEMBL9868 | 0.70 | AKT1 (0.46) | NPC1USP2ALDH1A1PKM | |
| SCHEMBL87533 | 0.69 | — | — | |
| SCHEMBL3480472 | 0.69 | CTRC (0.33) | CYP3A4CDK5 | |
| SCHEMBL3449914 | 0.69 | CYP2A6 (0.41) | CYP2A6FYNCYP2B6CYP2E1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | claimed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | claimed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | claimed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | claimed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| CN-110423239-A | 1,3- oxazines and 1,2,3- triazole derivative and its synthetic method and application | UNIV KUNMING SCIENCE & TECHNOLOGY | 2019-11-08 | — | — | CN | disclosed |
| EP-2782922-B1 | ANTIBACTERIAL TYLOSIN DERIVATIVES AND METHODS FOR THEIR PREPARATION | BAYER IP GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-9593140-B2 | Antibacterial tylosin derivatives and methods for their preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-14 | — | — | US | disclosed |
| US-20140349954-A1 | ANTIBACTERIAL TYLOSIN DERIVATIVES AND METHODS FOR THEIR PREPARATION | ELANCO ANIMAL HEALTH GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| EP-2782922-A1 | ANTIBACTERIAL TYLOSIN DERIVATIVES AND METHODS FOR THEIR PREPARATION | Bayer Intellectual Property GmbH (DE) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013076169-A1 | ANTIBACTERIAL TYLOSIN DERIVATIVES AND METHODS FOR THEIR PREPARATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-30 | — | — | WO | disclosed |
| US-20070077641-A1 | Methionine aminopeptidase and methods of use | PALMER LESLIE | 2007-04-05 | — | — | US | disclosed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1624849-A2 | METHIONINE AMINOPEPTIDASE AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005016237-A2 | METHIONINE AMINOPEPTIDASE AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | METAP1, METAP2, DNPEP | CYP2A6 3849/4885FYN 4274/4885CYP2B6 4031/4885 |
| US-20030220371-A1 | Compounds and methods | METAP2, METAP1, DNPEP | CYP2A6 2875/4885FYN 4543/4885CYP2B6 3399/4885 |
| US-20140349954-A1 | ANTIBACTERIAL TYLOSIN DERIVATIVES AND METHODS FOR THEIR PREPARATION | MLN, TMSB10, TMSB4X | CYP2A6 1058/4885FYN 3255/4885CYP2B6 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.